The assessment of antagonist potency under conditions of transient response kinetics

Arthur Christopoulos, Ann M. Parsons, Michael J. Lew, Esam E. El-Fakahany

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The muscarinic acetylcholine receptor antagonists, atropine and pirenzepine, produced an apparent insurmountable antagonism of muscarinic M1 receptor-mediated intracellular Ca2+ mobilization in Chinese hamster ovary (CHO) cells when tested against the agonists carbachol or xanomeline. Each antagonist caused a dextral shift of the agonist concentration-response curves with depression of the maximum response that was incomplete (i.e., saturated) and which varied with the pairs of agonist and antagonist. Equilibrium competition binding assays found no deviation from simple, reversible competitive behavior for either antagonist. The relative rates of dissociation of unlabeled atropine and pirenzepine were also assessed in radioligand kinetic studies and it was found that atropine dissociated from the receptor approximately 8-fold slower than pirenzepine. Numerical dynamic simulations suggested that the insurmountability of antagonism observed in the present study was probably a kinetic artifact related to the measurement of transient responses to a non-equilibrated agonist in the presence of a slowly dissociating antagonist. Importantly, the patterns of antagonism observed included a saturable depression of agonist maximal response, a mode of antagonism that is incompatible with the previously described phenomenon of hemi-equilibrium states. Monte Carlo simulations indicated that reasonable, semi-quantitative estimates of antagonist potency could be determined by a minor modification of standard methods, where equieffective agonist concentrations, rather than EC50 values, are compared in the absence and presence of antagonist. Application of the latter approach to the functional data yielded estimates of antagonist potency that were in excellent agreement with those derived from the equilibrium binding assays, thus indicating that the present method can be useful for quantifying antagonist potency under non-equilibrium conditions. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)217-227
Number of pages11
JournalEuropean Journal of Pharmacology
Volume382
Issue number3
DOIs
Publication statusPublished - 15 Oct 1999
Externally publishedYes

Keywords

  • Antagonism
  • Ca mobilization
  • Insurmountable
  • Kinetics
  • Monte Carlo simulation
  • Muscarinic receptor
  • Transient response

Cite this

Christopoulos, Arthur ; Parsons, Ann M. ; Lew, Michael J. ; El-Fakahany, Esam E. / The assessment of antagonist potency under conditions of transient response kinetics. In: European Journal of Pharmacology. 1999 ; Vol. 382, No. 3. pp. 217-227.
@article{9782a852834b436786d1243a02d4cc76,
title = "The assessment of antagonist potency under conditions of transient response kinetics",
abstract = "The muscarinic acetylcholine receptor antagonists, atropine and pirenzepine, produced an apparent insurmountable antagonism of muscarinic M1 receptor-mediated intracellular Ca2+ mobilization in Chinese hamster ovary (CHO) cells when tested against the agonists carbachol or xanomeline. Each antagonist caused a dextral shift of the agonist concentration-response curves with depression of the maximum response that was incomplete (i.e., saturated) and which varied with the pairs of agonist and antagonist. Equilibrium competition binding assays found no deviation from simple, reversible competitive behavior for either antagonist. The relative rates of dissociation of unlabeled atropine and pirenzepine were also assessed in radioligand kinetic studies and it was found that atropine dissociated from the receptor approximately 8-fold slower than pirenzepine. Numerical dynamic simulations suggested that the insurmountability of antagonism observed in the present study was probably a kinetic artifact related to the measurement of transient responses to a non-equilibrated agonist in the presence of a slowly dissociating antagonist. Importantly, the patterns of antagonism observed included a saturable depression of agonist maximal response, a mode of antagonism that is incompatible with the previously described phenomenon of hemi-equilibrium states. Monte Carlo simulations indicated that reasonable, semi-quantitative estimates of antagonist potency could be determined by a minor modification of standard methods, where equieffective agonist concentrations, rather than EC50 values, are compared in the absence and presence of antagonist. Application of the latter approach to the functional data yielded estimates of antagonist potency that were in excellent agreement with those derived from the equilibrium binding assays, thus indicating that the present method can be useful for quantifying antagonist potency under non-equilibrium conditions. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Antagonism, Ca mobilization, Insurmountable, Kinetics, Monte Carlo simulation, Muscarinic receptor, Transient response",
author = "Arthur Christopoulos and Parsons, {Ann M.} and Lew, {Michael J.} and El-Fakahany, {Esam E.}",
year = "1999",
month = "10",
day = "15",
doi = "10.1016/S0014-2999(99)00550-6",
language = "English",
volume = "382",
pages = "217--227",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

The assessment of antagonist potency under conditions of transient response kinetics. / Christopoulos, Arthur; Parsons, Ann M.; Lew, Michael J.; El-Fakahany, Esam E.

In: European Journal of Pharmacology, Vol. 382, No. 3, 15.10.1999, p. 217-227.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The assessment of antagonist potency under conditions of transient response kinetics

AU - Christopoulos, Arthur

AU - Parsons, Ann M.

AU - Lew, Michael J.

AU - El-Fakahany, Esam E.

PY - 1999/10/15

Y1 - 1999/10/15

N2 - The muscarinic acetylcholine receptor antagonists, atropine and pirenzepine, produced an apparent insurmountable antagonism of muscarinic M1 receptor-mediated intracellular Ca2+ mobilization in Chinese hamster ovary (CHO) cells when tested against the agonists carbachol or xanomeline. Each antagonist caused a dextral shift of the agonist concentration-response curves with depression of the maximum response that was incomplete (i.e., saturated) and which varied with the pairs of agonist and antagonist. Equilibrium competition binding assays found no deviation from simple, reversible competitive behavior for either antagonist. The relative rates of dissociation of unlabeled atropine and pirenzepine were also assessed in radioligand kinetic studies and it was found that atropine dissociated from the receptor approximately 8-fold slower than pirenzepine. Numerical dynamic simulations suggested that the insurmountability of antagonism observed in the present study was probably a kinetic artifact related to the measurement of transient responses to a non-equilibrated agonist in the presence of a slowly dissociating antagonist. Importantly, the patterns of antagonism observed included a saturable depression of agonist maximal response, a mode of antagonism that is incompatible with the previously described phenomenon of hemi-equilibrium states. Monte Carlo simulations indicated that reasonable, semi-quantitative estimates of antagonist potency could be determined by a minor modification of standard methods, where equieffective agonist concentrations, rather than EC50 values, are compared in the absence and presence of antagonist. Application of the latter approach to the functional data yielded estimates of antagonist potency that were in excellent agreement with those derived from the equilibrium binding assays, thus indicating that the present method can be useful for quantifying antagonist potency under non-equilibrium conditions. Copyright (C) 1999 Elsevier Science B.V.

AB - The muscarinic acetylcholine receptor antagonists, atropine and pirenzepine, produced an apparent insurmountable antagonism of muscarinic M1 receptor-mediated intracellular Ca2+ mobilization in Chinese hamster ovary (CHO) cells when tested against the agonists carbachol or xanomeline. Each antagonist caused a dextral shift of the agonist concentration-response curves with depression of the maximum response that was incomplete (i.e., saturated) and which varied with the pairs of agonist and antagonist. Equilibrium competition binding assays found no deviation from simple, reversible competitive behavior for either antagonist. The relative rates of dissociation of unlabeled atropine and pirenzepine were also assessed in radioligand kinetic studies and it was found that atropine dissociated from the receptor approximately 8-fold slower than pirenzepine. Numerical dynamic simulations suggested that the insurmountability of antagonism observed in the present study was probably a kinetic artifact related to the measurement of transient responses to a non-equilibrated agonist in the presence of a slowly dissociating antagonist. Importantly, the patterns of antagonism observed included a saturable depression of agonist maximal response, a mode of antagonism that is incompatible with the previously described phenomenon of hemi-equilibrium states. Monte Carlo simulations indicated that reasonable, semi-quantitative estimates of antagonist potency could be determined by a minor modification of standard methods, where equieffective agonist concentrations, rather than EC50 values, are compared in the absence and presence of antagonist. Application of the latter approach to the functional data yielded estimates of antagonist potency that were in excellent agreement with those derived from the equilibrium binding assays, thus indicating that the present method can be useful for quantifying antagonist potency under non-equilibrium conditions. Copyright (C) 1999 Elsevier Science B.V.

KW - Antagonism

KW - Ca mobilization

KW - Insurmountable

KW - Kinetics

KW - Monte Carlo simulation

KW - Muscarinic receptor

KW - Transient response

UR - http://www.scopus.com/inward/record.url?scp=0032732550&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(99)00550-6

DO - 10.1016/S0014-2999(99)00550-6

M3 - Article

VL - 382

SP - 217

EP - 227

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -